2022
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyImaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2019
Diagnosing acute interstitial nephritis: considerations for clinicians
Nussbaum E, Perazella M. Diagnosing acute interstitial nephritis: considerations for clinicians. Clinical Kidney Journal 2019, 12: 808-813. DOI: 10.1093/ckj/sfz080.Peer-Reviewed Original ResearchAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisInterstitial nephritisCommon causeDirect further managementKidney injuryMost patientsTubular necrosisKidney biopsyClinical historyFurther managementCliniciansLaboratory dataNephritisPatientsInjuryDiagnosisSingle testCauseBiopsyNecrosisBiomarkers
2004
Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients
Perazella M, Brewster U, Perazella M. Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients. Seminars In Dialysis 2004, 17: 57-60. PMID: 14717813, DOI: 10.1111/j.1525-139x.2004.17115.x.BooksConceptsInnate immune responseRisk of infectionIntravenous ironEnd-stage renal disease patientsHost innate immune responseRenal disease patientsIron-deficient patientsAdministration of ironOral ironIron therapyMost patientsHemodialysis patientsActive infectionDisease patientsIron preparationsIron overloadAllergic reactionsClinical studiesImmune responsePatientsBacterial infectionsIron deficiencyInfectionRiskBacterial growth
1999
Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem?
Alappan R, Buller G, Perazella M. Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem? American Journal Of Nephrology 1999, 19: 389-394. PMID: 10393376, DOI: 10.1159/000013483.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsTrimethoprim-sulfamethoxazole therapyBaseline serum potassium concentrationVariety of infectionsCreatinine levelsDay 5Treatment groupsPotassium concentrationControl groupMean serum potassium concentrationBlood urea nitrogen levelsDevelopment of hyperkalemiaLife-threatening hyperkalemiaMild renal insufficiencyDays of therapyHigher serum potassium concentrationsImmunodeficiency syndrome (AIDS) patientsUrea nitrogen levelsSerum glucose concentrationRelevant hyperkalemiaOral antibioticsRenal insufficiencyMost patientsSevere hyperkalemia